Andros
Kraken
- Joined
- Jan 14, 2020
- Posts
- 3,701
- Reputation
- 6,126
Finasteride adverse effects and post-finasteride syndrome; implications for dentists
We intend to present in this study several oral adverse effects encountered during finasteride administration, represented by mild and moderate signs which generally responded to topical procedures without to require the stop of the drug administration
Recent studies show that finasteride side effects can occur at the level of oral cavity too, in the form of various signs and symptoms (erythema, purpura, gingival hypertrophy)
The study group taking finasteride was represented by eighty four subjects with androgenic alopecia, who received the drug 1 mg daily, six month or more.
On our sample, the most notable adverse effects encountered during therapeutic phase were as follow: depression (8,33%), gastrointestinal disturbances (5,95%), decreased libido (7,14%) and erectile dysfunction (2,38%). At four months after finasteride cessation, the “post-finasteride” syndrome was represented by depression (4,76%), erectile dysfunction (1,19%) and ejaculation disorders (2,38%).
The gingivo-parodontal lesions were encountered during finasteride administration at 21,42% subjects: 6 with mucosal pallor, 5 with erythema, 3 with purpura, 2 with periodontal inflammation, and 2 with gingival hypertrophy. Excepting the two patients with gingival hypertrophy who required discontinuation of finasteride to be ameliorated (regressing totally in less than three months after finasteride cessation), the other oral lesions were treated through specific/ local procedures, without to be necessary to stop the finasteride administration.
Conversion of testosterone to DHT is increased in gingival inflammation. Yet, DHT is considered to be an important stimulator of fibroblast activity. Starting from these findings, some authors suggested that finasteride can be used in the form of topical application (in a suitable vehicle) to partially block the proliferation of fibroblast hyperplasia following phenytoin administration.
Testosterone-specific receptors have been isolated from periodontal tissue levels. The number of receptors in the gingival fibroblasts tends to increase inflammation or gingival hyperplasia. At the gingival level, testosterone stimulates the matrix synthesis via osteoblasts and fibroblasts from periodontal ligament, stimulates the proliferation and differentiation of osteoblasts, reduce the production of IL-6 during inflammation through inhibition of prostaglandin, increase the concentration of osteoprotegerin. As a conclusion, finasteride adverse effects encountered on our sample at the level of marginal periodontium could be the consequences of a direct finasteride action, and possible indirect consequences of subsequent androgenic interferences.
We intend to present in this study several oral adverse effects encountered during finasteride administration, represented by mild and moderate signs which generally responded to topical procedures without to require the stop of the drug administration
Recent studies show that finasteride side effects can occur at the level of oral cavity too, in the form of various signs and symptoms (erythema, purpura, gingival hypertrophy)
The study group taking finasteride was represented by eighty four subjects with androgenic alopecia, who received the drug 1 mg daily, six month or more.
On our sample, the most notable adverse effects encountered during therapeutic phase were as follow: depression (8,33%), gastrointestinal disturbances (5,95%), decreased libido (7,14%) and erectile dysfunction (2,38%). At four months after finasteride cessation, the “post-finasteride” syndrome was represented by depression (4,76%), erectile dysfunction (1,19%) and ejaculation disorders (2,38%).
The gingivo-parodontal lesions were encountered during finasteride administration at 21,42% subjects: 6 with mucosal pallor, 5 with erythema, 3 with purpura, 2 with periodontal inflammation, and 2 with gingival hypertrophy. Excepting the two patients with gingival hypertrophy who required discontinuation of finasteride to be ameliorated (regressing totally in less than three months after finasteride cessation), the other oral lesions were treated through specific/ local procedures, without to be necessary to stop the finasteride administration.
Conversion of testosterone to DHT is increased in gingival inflammation. Yet, DHT is considered to be an important stimulator of fibroblast activity. Starting from these findings, some authors suggested that finasteride can be used in the form of topical application (in a suitable vehicle) to partially block the proliferation of fibroblast hyperplasia following phenytoin administration.
Testosterone-specific receptors have been isolated from periodontal tissue levels. The number of receptors in the gingival fibroblasts tends to increase inflammation or gingival hyperplasia. At the gingival level, testosterone stimulates the matrix synthesis via osteoblasts and fibroblasts from periodontal ligament, stimulates the proliferation and differentiation of osteoblasts, reduce the production of IL-6 during inflammation through inhibition of prostaglandin, increase the concentration of osteoprotegerin. As a conclusion, finasteride adverse effects encountered on our sample at the level of marginal periodontium could be the consequences of a direct finasteride action, and possible indirect consequences of subsequent androgenic interferences.
